7Beurei E,Blivet-Van Eggelpoel MJ. Glycogen synthasc kinase-3 inhibitors augment TRAIL induced apoptotic death in human hepatoma cells[J].Biochemical Pharmacology,2009,(01):54-65.doi:10.1016/j.bcp.2008.09.026.
8Giese KP. GSK-3:a key player in neurodegeneration and m emory[J].IUBMB Life,2009,(05):516-521.doi:10.1002/iub.187.
9Sun Q,Gamblin TC. Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polym erization[J].Biochemistry,2009,(25):6002-6011.
10Muyllaert D,Kremer A,Jaworski T. Glycogen synthase kinase-3beta,or a link between amyloid and tan pathology[J].Genes Brain and Behavior,2008,(Suppl 1):57-66.
6BIESSELS G J,KAPPELLE L J. Increased risk of Alzheimer' s disease in type Ⅱ diabetes : insulin resistance of the brain or insulin-induced amyloid pathology? [J]. Biochem Soc Trans, 2005,33 (11) : 1041-1044.
7SIMA A A, LI Z G. Diabetes and Alzheimer's disease-Is there a connection? [J]. Rev Diabet Stud, 2006, 3(4):161- 168.
8BIESSELS G J, STAEKENBORG S, BRUNNER E, et at. Risk of dementia in diabetes mellitus: a systematic review [J]. Lancet Neurol,2006,5(1) :64-74.
9LI Z G,ZHANG W,SIMA A A. Alzheimer-like changes in rat models of spontaneous diahetes[J]. Diabetes, 2007, 56 (7) : 1817-1824.
10GONG C X,LIU F,GRUNDKE-IQBAL I,et al. Post-translational modifications of tau protein in Alzheimer's disease [J]. J Neural Transm,2005,112(6) :813-818.
